CMMB — Chemomab Therapeutics Ltd.

Chemomab Therapeutics Q1 2023 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2023, Chemomab reported cash, cash equivalents, and bank deposits of $32.8 million, down from approximately $40 million at year-end 2022.
• R&D Expenses: Increased significantly to $6.9 million for Q1 2023, up 151% from $2.7 million in Q1 2022, primarily due to heightened clinical and preclinical activities.
• G&A Expenses: Decreased to $2.2 million from $2.6 million year-over-year, attributed to lower noncash share-based expenses and insurance costs.
• Net Loss: Reported at $8.8 million, or approximately $0.04 per share, compared to a net loss of $5.1 million, or $0.02 per share, in the same period last year.
• Cash Runway: Extended from March 31, 2024, to June 30, 2024, due to budget reviews that trimmed expenditures while maintaining clinical program resources.

2. Strategic Updates and Business Highlights

• CM-101 Phase 2 Trial Results: Positive top-line results from a Phase 2 trial in liver fibrosis related to NASH were reported, showing safety and improvements in multiple biomarkers.
• Clinical Progress: Advancements in the CM-101 program for primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc) were highlighted, with plans to report top-line data from the PSC trial in the second half of 2024.
• New Executive Appointments: Addition of Dr. Matt Frankel as Chief Medical Officer and Dr. Mitch Jones as Vice President of Corporate Development, enhancing the leadership team’s capabilities.

3. Forward Guidance and Outlook

• Clinical Trials: Anticipation of opening initial U.S. sites for the SSc trial around midyear 2023, with data expected in late 2024.
• Scientific Engagement: Plans to present at major medical conferences, including EASL and EULAR, to share findings and enhance visibility in the fibro-inflammatory disease space.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: The biotech sector remains challenging, impacting stock performance and funding opportunities.
• Increased Expenses: Substantial rise in R&D costs could pressure financial resources, despite the extended cash runway.
• Focus on NASH: While there is interest in NASH, Chemomab has no immediate plans for further trials in this area, which may limit potential partnerships or revenue opportunities in a promising market.

5. Notable Q&A Insights

• Partnership Discussions: Chemomab is in dialogue with various companies regarding CM-101, including potential interest in NASH, despite not pursuing trials independently.
• SSc Trial Design: The decision to use a lower dose (10 mg/kg) was based on FDA guidance to demonstrate tissue effects effectively, and the inclusion of both limited and diffuse SSc patients aims to address a broader patient population and unmet needs.
• Scientific Communication: The company is focused on ensuring that the scientific community is informed about their progress and findings, reflecting a commitment to transparency and engagement with stakeholders.

Overall, Chemomab is making significant strides in its clinical programs while navigating financial challenges and market conditions. The company remains optimistic about the potential of CM-101 in treating rare fibro-inflammatory diseases.